Thus, several TGF-β inhibitors are now being evaluated in clinical trials in breast cancer where they generated either disappointing (NCT01401062) or mixed results (Bogdahn et al., 2011; Giaccone et al., 2015). This evidence concerns the gene TGFB1 and breast cancer.